107 related articles for article (PubMed ID: 15710845)
1. Mouse models of human neurodegenerative disorders: requirements for medication development.
Bloom FE; Reilly JF; Redwine JM; Wu CC; Young WG; Morrison JH
Arch Neurol; 2005 Feb; 62(2):185-7. PubMed ID: 15710845
[TBL] [Abstract][Full Text] [Related]
2. A decade of modeling Alzheimer's disease in transgenic mice.
McGowan E; Eriksen J; Hutton M
Trends Genet; 2006 May; 22(5):281-9. PubMed ID: 16567017
[TBL] [Abstract][Full Text] [Related]
3. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
Zhang Q; Zhang X; Sun A
Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923
[TBL] [Abstract][Full Text] [Related]
4. What transgenic mice tell us about neurodegenerative disease.
Gurney ME
Bioessays; 2000 Mar; 22(3):297-304. PubMed ID: 10684590
[TBL] [Abstract][Full Text] [Related]
5. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
6. Inherited neurodegenerative diseases and transgenic models.
Borchelt DR
Lab Anim Sci; 1998 Dec; 48(6):604-10. PubMed ID: 10090084
[No Abstract] [Full Text] [Related]
7. Metallothionein-I and -III expression in animal models of Alzheimer disease.
Carrasco J; Adlard P; Cotman C; Quintana A; Penkowa M; Xu F; Van Nostrand WE; Hidalgo J
Neuroscience; 2006 Dec; 143(4):911-22. PubMed ID: 17027170
[TBL] [Abstract][Full Text] [Related]
8. Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models.
Van Dam D; Marescau B; Engelborghs S; Cremers T; Mulder J; Staufenbiel M; De Deyn PP
Neurochem Int; 2005 Apr; 46(5):409-22. PubMed ID: 15737439
[TBL] [Abstract][Full Text] [Related]
9. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease.
Kobayashi DT; Chen KS
Genes Brain Behav; 2005 Apr; 4(3):173-96. PubMed ID: 15810905
[TBL] [Abstract][Full Text] [Related]
10. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease.
Garcia-Alloza M; Robbins EM; Zhang-Nunes SX; Purcell SM; Betensky RA; Raju S; Prada C; Greenberg SM; Bacskai BJ; Frosch MP
Neurobiol Dis; 2006 Dec; 24(3):516-24. PubMed ID: 17029828
[TBL] [Abstract][Full Text] [Related]
11. Creating the mouse that roared.
Emerson D
Minn Med; 2001 May; 84(5):6-9. PubMed ID: 11398634
[No Abstract] [Full Text] [Related]
12. Conditionally inducible tau mice--designing a better mouse model of neurodegenerative diseases.
Janus C
Genes Brain Behav; 2008 Feb; 7 Suppl 1():12-27. PubMed ID: 18184367
[TBL] [Abstract][Full Text] [Related]
13. Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease.
Van Broeck B; Vanhoutte G; Pirici D; Van Dam D; Wils H; Cuijt I; Vennekens K; Zabielski M; Michalik A; Theuns J; De Deyn PP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
Neurobiol Aging; 2008 Feb; 29(2):241-52. PubMed ID: 17112635
[TBL] [Abstract][Full Text] [Related]
14. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
Rockenstein E; Crews L; Masliah E
Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
[TBL] [Abstract][Full Text] [Related]
15. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
Götz J; Ittner LM; Kins S
J Neurochem; 2006 Aug; 98(4):993-1006. PubMed ID: 16787410
[TBL] [Abstract][Full Text] [Related]
16. Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models.
Mi W; Pawlik M; Sastre M; Jung SS; Radvinsky DS; Klein AM; Sommer J; Schmidt SD; Nixon RA; Mathews PM; Levy E
Nat Genet; 2007 Dec; 39(12):1440-2. PubMed ID: 18026100
[TBL] [Abstract][Full Text] [Related]
17. Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw.
Spires TL; Hannan AJ
FEBS J; 2005 May; 272(10):2347-61. PubMed ID: 15885086
[TBL] [Abstract][Full Text] [Related]
18. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease.
Pihlaja R; Koistinaho J; Malm T; Sikkilä H; Vainio S; Koistinaho M
Glia; 2008 Jan; 56(2):154-63. PubMed ID: 18004725
[TBL] [Abstract][Full Text] [Related]
19. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease.
El Tannir El Tayara N; Delatour B; Le Cudennec C; Guégan M; Volk A; Dhenain M
Neurobiol Dis; 2006 Apr; 22(1):199-208. PubMed ID: 16337798
[TBL] [Abstract][Full Text] [Related]
20. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition.
Flood DG; Lin YG; Lang DM; Trusko SP; Hirsch JD; Savage MJ; Scott RW; Howland DS
Neurobiol Aging; 2009 Jul; 30(7):1078-90. PubMed ID: 18053619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
